Abstract
Silybin, a major constituent of the milk thistle, is used to treat several liver disorders. Silybin inactivated purified, recombinant cytochromes P450 (P450) 3A4 and 2C9 in a mechanism-based manner. The inactivations were time-, concentration-, and NADPH-dependent. The inactivation of the 7-benzyloxy-4-(trifluoromethyl-)coumarin O-debenzylation activity (P450 3A4) was characterized by a KI of 32 μM, a kinact of 0.06 min-1, and a t1/2 of 14 min. Testosterone metabolism to 6-β-hydroxytestosterone (P450 3A4) was also inactivated with a KI of 166 μM, a kinact of 0.08 min-1, and a t1/2 of 9 min. The 7-ethoxy-4-(trifluoromethyl)coumarin O-deethylation activity of purified human P450 2C9 was inactivated with a KI of 5 μM, a kinact of 0.14 min-1, and a t1/2 of 7 min. Parallel loss of heme was observed with both P450s. Activity of both P450 enzymes was not recovered after removal of silybin either by dialysis or by spin gel filtration. In addition, silybin inhibited the glucuronidation of 7-hydroxy-4-trifluoromethylcoumarin catalyzed by recombinant hepatic UDP-glucuronosyltransferases (UGTs) 1A1, 1A6, 1A9, 2B7, and 2B15, with IC50 values of 1.4 μM, 28 μM, 20 μM, 92 μM, and 75 μM, respectively. Silybin was a potent inhibitor of UGT1A1 and was 14- and 20-fold more selective for UGT1A1 than for UGT1A9 and UGT1A6, respectively. Thus, careful administration of silybin with drugs primarily cleared by P450s 3A4 or 2C9 is advised, since drug-drug interactions cannot be excluded. The clinical significance of in vitro UGT1A1 inhibition is unknown.
Footnotes
-
↵1 Abbreviations used are: P450, cytochrome P450; GSH, glutathione; BSA, bovine serum albumin; BFC, 7-benzyloxy-4-(trifluoromethyl)coumarin; 7EFC, 7-ethoxy-4-(trifluoromethyl)coumarin; DMSO, dimethyl sulfoxide; HPLC, high-performance liquid chromatography; reductase, NADPH-cytochrome P450 reductase; UDPGA, uridine diphosphoglucuronic acid; UGT, UDP-glucuronosyltransferase; HFC, 7-hydroxy-4-(trifluoromethyl)coumarin; SN-38, 7-ethyl-10-hydroxycamptothecin.
-
This research was supported in part by Grant CA 16954 from the National Cancer Institute.
- Received October 24, 2003.
- Accepted February 23, 2004.
- The American Society for Pharmacology and Experimental Therapeutics
DMD articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|